1-3 of 3
Samiulla Dhodheri
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity

Tim H. Holmström, Anu-Maarit Moilanen, Tarja Ikonen, Mari L. Björkman, Tero Linnanen, Gerd Wohlfahrt, Stefan Karlsson, Riikka Oksala, Timo Korjamo, Susanta Samajdar, Srinivasan Rajagopalan, Shekar Chelur, Kishore Narayanan, Raghuveer K. Ramachandra, Jiju Mani, Rashmi Nair, Nagaraj Gowda, Thomas Anthony, Samiulla Dhodheri, Subhendu Mukherjee, Ravi K. Ujjinamatada, Nanduri Srinivas, Murali Ramachandra, Pekka J. Kallio
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2019) 18 (1): 28–38.
https://doi.org/10.1158/1535-7163.MCT-18-0204
Published: 02 January 2019
View article titled, ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity
Open the PDF for ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity in another window
Includes: Supplementary data
Journal Articles

Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases

Maximilien Murone, Anne Vaslin Chessex, Antoine Attinger, Raghuveer Ramachandra, Shankar J. Shetty, Girish Daginakatte, Saumitra Sengupta, Sivapriya Marappan, Samiulla Dhodheri, Stefania Rigotti, Yogeshwar Bachhav, Silvano Brienza, Peter Traxler, Marc Lang, Michel Aguet, Vincent Zoete, Olivier Michielin, Courtney Nicholas, Faye M. Johnson, Murali Ramachandra, Andres McAllister
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (10): 2334–2343.
https://doi.org/10.1158/1535-7163.MCT-15-0974
Published: 02 October 2016
View article titled, Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases
Open the PDF for Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases in another window
Includes: Supplementary data
Journal Articles

Abstract A96: First-in-class orally available immune checkpoint antagonists for cancer therapy

Pottayil G. Sasikumar, Sudarshan S. Naremaddepalli, Nagaraj Gowda, Sreenivas Adurthi, Samiulla Dhodheri, Amit Dhudashia, Raghuveer Ramachandra, Murali Ramachandra
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): A96.
https://doi.org/10.1158/1535-7163.TARG-15-A96
Published: 01 December 2015
View article titled, Abstract A96: First-in-class orally available immune checkpoint antagonists for cancer therapy